News for BridgeBio Pharma, Inc. (BBIO)

BridgeBio Pharma, Inc. (NASDAQ:BBIO) is one of the 13 Biotech Stocks with Huge Upside Potential. In a recent report, Raghuram Selvaraju, an expert at H.C.

In a recent analysis, H.C. Wainwright's expert, Raghuram Selvaraju, has increased the price target for BridgeBio (BBIO) from $53 to $56, while maintaining a Buy

BMO Capital has adjusted its price target for BridgeBio (BBIO), increasing it from $37 to $42 while maintaining a Market Perform rating. The firm predicts that

BridgeBio's Attruby surpasses expectations with booming Q1 revenue and strong market positioning. Read why BBIO stock is rated a Strong Buy.

Summary BridgeBio Pharma Inc (BBIO), a biopharmaceutical company dedicated to developing transformative medicines for genetic diseases, announced its participat

PALO ALTO, Calif., June 02, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. ( BBIO) (”œBridgeBio” or the ”œCompany”), a new type of biopharmaceutical co

BridgeBio Pharma (BBIO) to attend the Goldman Sachs 46th Annual Global Healthcare Conference 2025. Fireside chat scheduled for June 9, 2025, at 8:40 am

BridgeBio Pharma, Inc.'s stock soars on Attruby's launch and licensing deals. Click for more on BBIO growth, competition, and late-stage pipeline catalysts.

On March 31, 2025, Prosight Management, LP (Trades, Portfolio) made a strategic decision to reduce its stake in MeiraGTx Holdings PLC by 34,266 shares. The tran

Summary BridgeBio Pharma Inc (BBIO), a biopharmaceutical company focused on genetic diseases, has released promising data from its Phase 3 trial of acoramidis,

We recently published an article titled Massive Sell-Offs Just Hit These 10 Stocks Today.

We recently published an article titled Massive Sell-Offs Just Hit These 10 Stocks Today. In this article, we are going to take a look at where BridgeBio Pharma, Inc. (NASDAQ:BBIO) stands against the other stocks. Wall Street’s main indices finished mixed on Tuesday, as investors digested the country’s latest inflation figures, which came out lower than […]

BridgeBio Pharma (BBIO) to present new findings at the Heart Failure 2025 conference in Serbia. Focus on acoramidis for treating transthyretin amyloid c

PALO ALTO, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. ( BBIO) (”œBridgeBio” or the ”œCompany”), a new type of biopharmaceutical com

BridgeBio Pharma (BBIO) will participate in the Bank of America Merrill Lynch Global Healthcare Conference 2025. The presentation will be held on Wednes

We recently published an article titled Excellent Earnings Propelled Prices of These 10 Firms. In this article, we are going to take a look at where BridgeBio Pharma, Inc. (NASDAQ:BBIO) stands against the other stocks that soared on Wednesday. The stock market finished Wednesday’s trading on a lackluster note, with the three major indices finishing mixed, as […]

We recently published an article titled Excellent Earnings Propelled Prices of These 10 Firms. In this article, we are going to take a look at where BridgeBio Pharma, Inc. (NASDAQ:BBIO) stands against...

Analyst Greg Harrison from Scotiabank has elevated the price target for BridgeBio (BBIO) to $55, up from the previous target of $52, while maintaining an Outper

The financial firm UBS has upgraded its price target for BridgeBio (BBIO) from $65 to $72 while maintaining a Buy rating on the company's shares. According to U